| 24th week of 2015 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20150157650 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE - Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis. | 2015-06-11 |
| 20150157651 | TRI-SUBSTITUTED GLYCEROL COMPOUNDS FOR USE IN THE TREATMENT OF CLINICALLY ISOLATED SYNDROME AND/OR MULTIPLE SCLEROSIS - The present invention relates to tri-substituted glycerol compounds according to formula (I) as described herein for use in the treatment of clinically isolated syndrome, relapsing remitting multiple sclerosis (RR-MS) and/or secondary progressive multiple sclerosis (SP-MS). The tri-substituted glycerol compounds according to formula (I) as described herein may also be used for the treatment of multiple sclerosis patients not adequately responding to interferon therapy. The present invention also relates to a tri-substituted glycerol compound as described herein, for use as a medicament, wherein the tri-substituted glycerol compound is administered in combination with at least one further pharmaceutically active compound. | 2015-06-11 |
| 20150157652 | VELIPARIB IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER - The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care. | 2015-06-11 |
| 20150157653 | Prevention of Clostridium Difficile Infection in High Risk Patients - The present invention relates to methods of preventing | 2015-06-11 |
| 20150157654 | RUTIN-RICH EXTRACT AND METHOD OF MAKING SAME - A method of obtaining a rutin-rich extract from a plant and a rutin-rich extract of | 2015-06-11 |
| 20150157655 | SELENIUM CONTAINING NUCLEOSIDES AS NUTRITIONAL SUPPLEMENTS - Nutritional supplements are described comprising selenium containing nucleosides. Methods of making the nutritional supplements and using the nutritional supplements are also described. | 2015-06-11 |
| 20150157656 | Method for Treatment of Castration-Resistant Prostate Cancer - Castrate resistant prostate cancer cell lines exhibiting resistance to the androgen-receptor antagonist enzaluatamide overexpress one or both of IGFBP-2 or IGFBP-5 when compared to non-resistant cell lines. Oligonucleotides that target IGFBP-2 and IGFBP-5 can be used to overcome this resistance or as part of a treatment program when administered concurrently with the administration of androgen-receptor antagonist treatments. | 2015-06-11 |
| 20150157657 | PREPARATION AND DELIVERY OF SUSTAINED NITRIC OXIDE RELEASING SOLUTIONS - The present invention relates to a system and method of treating a subject with nitric oxide gas and/or nitric oxide releasing solutions. The present invention also relates to compositions and devices useful for treating a subject with nitric oxide gas and/or nitric oxide releasing solutions. | 2015-06-11 |
| 20150157658 | Nitric Oxide Generating Medical Devices - Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided. | 2015-06-11 |
| 20150157659 | METHOD OF INDUCING AUTOPHAGY AND ACTIVATING TOLL-LIKE RECEPTOR - A method of inducing autophagy in a cell is achieved by contacting the cell with graphene oxide (GO) in an amount effective to induce autophagy in the cell, wherein the cell expresses at least one of TLR-4 (Toll-like receptor 4) and TLR-9 (Toll-like receptor 9). Differences between autophagy triggered by GO and other conventional agonists such as rapamycin have been observed. GO may activate autophagy in some cells that may not be triggered by rapamycin. The cell reveals no apparent apoptosis after treatment of the graphene oxide. A method of activating a Toll-like receptor in a cell is also herein provided. | 2015-06-11 |
| 20150157660 | NUTRITIONAL PRODUCT COMPOSITION FOR ENERGY - A nutritional product composition for energy, to increase intracellular ATP production, assist the body in making more energy without the use of caffeine and stimulants and combat fatigue on a cellular level. The nutritional product composition for energy includes a synergistic blend of nutrients and a silica gel that increases the rate of metabolism of cells to increase the rate of absorption of the nutrients and increase energy production. The synergistic blend of nutrients includes vitamin C, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, d-biotin, pantothenic acid, calcium, selenium, copper and chromium. The silica gel increases an absorption rate of the synergistic blend. | 2015-06-11 |
| 20150157661 | BIOCHAR PRODUCTS AND METHOD OF MANUFACTURE THEREOF - A method for producing biochar particles or pellets which use sulphur and other additives. The method includes producing a mixture with biochar and additives selected from sulphur, lignin, and gluten. The mixture is mixed with water and passed through an extruder to produce an extrudate. The extrudate is then cut into pellets. The pellets are then tumbled/spun with each other and heated to result in mostly spheroidal pellets whose mechanical characteristics allow them to be used with well-known agricultural equipment. The biochar can be produced with sulphur incorporated as an outer coating. To produce this sulphur coated biochar, the method includes feeding a biomass feedstock to a pyrolysis reactor, pyrolyzing the feedstock into biochar particles, size-sorting the biochar particles, and coating the biochar particles with the sulphur coating material. | 2015-06-11 |
| 20150157662 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS BY MODULATION OF DELTA-NP63 OR DCGR8 - The present invention generally concerns particular methods and compositions for generation of induced pluripotent stem cells. In particular aspects, induced pluripotent stem cells are generated from adult somatic cells following downregulation of a particular gene of interest. In some embodiments, induced pluripotent stem cells are generated from keratinocytes upon downregulation of ΔNp63 or DGCR8. | 2015-06-11 |
| 20150157663 | Pharmaceutical Composition Comprising Human-Blood-Derived-Cell Mass - There are provided a pharmaceutical composition for treating immune-related diseases, a pharmaceutical composition for treating ischemic diseases, a pharmaceutical composition for promoting lymphangiogenesis, a pharmaceutical composition for treating neurological diseases, a pharmaceutical composition for treating metabolic diseases, and the like, which contain blood-born hematospheres, and more specifically, may differentiate into inflammatory mononuclear cells, vascular endothelial cells, vascular smooth muscle cells, lymphatic vessel adult stem cells and progenitor cells, neural progenitor cells and nerve cells, insulin secreting cells, and the like by effective 3D culturing using blood mononuclear cells. Therefore, the present invention is expected to be used for development of a cell therapeutic agent for various types of diseases. Also, when blood-born hematospheres according to the present invention are used, it is possible to address previous problems associated with development of a stem cell therapeutic agent such as tumor occurrence, immune rejection, ethical issues, and difficult differentiation methods. | 2015-06-11 |
| 20150157664 | METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONS - Methods and compositions are provided for treating a subject for aging-associated conditions, e.g., cognitive impairment conditions. Aspects of the methods include administering a young plasma-comprising blood product to an individual in need thereof, e.g., an individual suffering from or at risk of developing the aging-associated condition, e.g., aging-associated cognitive impairment. Also provided are compositions and kits thereof that find use in practicing methods of the invention. | 2015-06-11 |
| 20150157665 | PATHODEN-INACTIVATED RED BLOOD CELL COMPOSITIONS - The present invention provides pathogen-inactivated red blood cell compositions suitable for infusion into a subject. | 2015-06-11 |
| 20150157666 | METHODS, SYSTEMS, AND COMPOSITIONS FOR CELL-DERIVED/VESICLE-BASED MICRORNA DELIVERY - Some embodiments comprise methods, systems, and compositions to produce and/or administer modified exosomes or other vesicles containing one or more selected microRNAs, including but not limited to, miR-146b. Some embodiments also comprise the therapeutic administration and use of such modified exosomes and/or producer cells to treat mammalian injuries and diseases, including in human beings. | 2015-06-11 |
| 20150157667 | METHOD FOR PREPARING DECELLULARIZED TISSUE PRODUCT, AND GRAFT PROVIDED WITH DECELLULARIZED TISSUE PRODUCT - Provided are: a method for preparing a decellularized tissue product in which decellularized tissue can be filled with liquid while changes in the structure of support tissue constituting the decellularized tissue are inhibited; and a graft provided with a decellularized tissue product. The method for preparing a decellularized tissue product includes a reduced-pressure step for bringing an animal-derived decellularized tissue material and a liquid into contact under reduced-pressure conditions, and/or a pressurized step for bringing same into contact under pressurized conditions. The graft is provided with a decellularized tissue product prepared by the method of preparation. | 2015-06-11 |
| 20150157668 | Methods Of Isolating Distinct Pancreatic Cell Types - Methods of isolating distinct specific cell types within mixed populations of cells. Methods of isolating specific cell types among pancreatic cells, particularly from human islets of Langerhans. Markers and combinations thereof for use in methods of isolating insulin producing islet beta cells for treatment of diabetes. | 2015-06-11 |
| 20150157669 | BIOEFFECTIVE KRILL OIL COMPOSITIONS - This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO | 2015-06-11 |
| 20150157670 | NON-CALORIC PROBIOTIC COMPOSITION AND METHOD OF PREPARATION - A probiotic composition comprising at least one viable probiotic microorganism having a biological or therapeutic activity in the gastrointestinal tract and a carrier suitable for human consumption is disclosed. The probiotic composition may contain drinking water and electrolytes and the probiotic microorganism may be spores of a probiotic microorganism. Also provided are methods of treating acute or chronic diarrhea and of improving immune function, digestive health, and/or intestinal flora by administering the probiotic composition. In addition, a food additive comprising at least one viable probiotic microorganism having a biological or therapeutic activity in the gastrointestinal tract and a carrier suitable for human consumption is provided. | 2015-06-11 |
| 20150157671 | NUTRITIONAL PRODUCT COMPOSITION FOR THE HEART - A nutritional product composition for the heart to promote optimal heart function, support normal heart muscle contractions, contribute to the protection of cells against oxidative stress, support macronutrient metabolism and create a synergistic blend of sustenance for the heart on a cellular level. The nutritional product composition for the heart includes a synergistic blend of nutrients and a silica gel that increases the rate of metabolism of cells to increase the rate of absorption of the nutrients and increase levels of magnesium. The synergistic blend of nutrients includes thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, magnesium and zinc. The silica gel increases an absorption rate of the synergistic blend. | 2015-06-11 |
| 20150157672 | KITS AND METHODS FOR SUSTAINED WEIGHT LOSS - Disclosed herein are compositions, methods and kits of effecting and prolonging weight loss by administering weight loss agents for treatment phases of predetermined durations. | 2015-06-11 |
| 20150157673 | METHOD FOR CONTROLLING OBESITY USING Antrodia camphorata - A method for controlling obesity by using | 2015-06-11 |
| 20150157674 | HERBAL COMPOSITION FOR VAGINAL TREATMENT - The present invention discloses a herbal formulation comprising therapeutic effective amount of plant extract of | 2015-06-11 |
| 20150157675 | COMPOSITION COMPRISING EUPATORIUM SPP. EXTRACT AS ACTIVE INGREDIENT FOR PREVENTING AND TREATING OBESITY AND METABOLIC BONE DISEASE - The present invention relates to a | 2015-06-11 |
| 20150157676 | WATER SOLUBLE DEFRUCTOSYLATED PEA EXTRACT, AND USE THEREOF AS A PREBIOTIC AGENT - The present invention relates to a water-soluble defructosylated pea extract, substantially free of proteins and peptides, as well as to an oligosaccharide composition such as that contained in said extract. It also relates to the method for preparing the same, and to the use thereof as a prebiotic agent. | 2015-06-11 |
| 20150157677 | NUTRITIONAL COMPOSITION FOR EQUINE REPRODUCTIVE HEATH - An equine nutritional composition comprising: i) a first component comprising micronutrients, wherein said micronutrients include: the amino acids L-carnitine, L-arginine, L-cysteine and, optionally, L-lysine; folate; and, at least one mineral element selected from the group consisting of: selenium, iron, calcium, magnesium, copper, zinc and manganese; and, ii) a second component comprising one or more fatty acids selected from each of the groups: omega-3 fatty acids; and, omega-6 fatty acids. The equine nutritional composition has utility in improving aspects of the reproductive health of stallions. | 2015-06-11 |
| 20150157678 | FEIJOA FRUIT EXTRACT - The invention relates to a | 2015-06-11 |
| 20150157679 | HERBAL FORMULATION FOR TREATING A MENSTRUAL-RELATED CONDITION - A formulation for treating a menstrual-related condition comprising a combination of the following herbs or extract(s) thereof: | 2015-06-11 |
| 20150157680 | MEDICINAL OROBANCHEACE EXTRACTS - Pharmaceutical extracts from Egyptian broomrape have proven efficacy against HCV and NAFLD. Compositions and method of making and using same are provided. | 2015-06-11 |
| 20150157681 | METHOD OF USING TRAUMEEL IN ORAL SURGICAL PROCEDURES - Methods of reducing inflammation, pain and bruising after oral surgery with intramucosal delivery of Traumeel are disclosed. | 2015-06-11 |
| 20150157683 | ANTI-DIABETIC NUTRACEUTICAL COMPOSITION FROM PALM LEAF EXTRACT - A comestible composition with anti-diabetic property which is effective in lowering the blood glucose and help reduce oxidative stress in diabetics and have anti-diabetic properties that protect against diabetic complications, retarding diabetes related organ degeneration and effective to hinder or prevent ailments or conditions resulting from, or exacerbated by, a chronic increase in blood sugar including: tissue degeneration, cardiovascular disease, kidney degeneration, loss of cognitive function, weight loss, visual impairment, and vasomotor symptoms which contains extract from palm leaf | 2015-06-11 |
| 20150157684 | Soft Protease Inhibitors and Pro-Soft Forms Thereof - The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 2015-06-11 |
| 20150157685 | METHODS FOR TREATMENT OF ATHEROSCLEROSIS - Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof. | 2015-06-11 |
| 20150157686 | TREATMENTS OF OXIDATIVE STRESS CONDITIONS - The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like. | 2015-06-11 |
| 20150157687 | Ophthalmic Compositions - The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles. | 2015-06-11 |
| 20150157688 | COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-KB - The present invention discloses a composition and method for effecting various cytokines and NF-κB by administering an effective amount of a phyto-percolate composition to an individual. In various exemplary embodiments, the composition is claimed to be useful for the effective treatment of inflammation, cancer, and/or various infections including HIV by regulation of various interleukins, such as IL-10 and IL-2, and of transcription factors including NF-κB. | 2015-06-11 |
| 20150157689 | RECOMBINANT HUMAN CC10 PROTEIN FOR TREATMENT OF INFLUENZA AND EBOLA - Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza and filovirus titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza and ebola infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza and ebola infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans. | 2015-06-11 |
| 20150157690 | Amyloid Beta Peptides as a Therapy for Inflammation - The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an amyloid beta peptide, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. | 2015-06-11 |
| 20150157691 | Galectin-3 to Treat Ovarian Cancer - The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt/NF-κB activation of the ovarian cancer. | 2015-06-11 |
| 20150157692 | METHODS OF TREATING OBESITY - The present invention relates to methods of treating and/or preventing obesity comprising the administration of an inhibitor of lymphotoxin, IL-22 and/or IL-23 to a subject having or at risk of developing obesity. | 2015-06-11 |
| 20150157693 | FOOD CONTAINING PROLACTIN - A nutritional composition for a subject, comprising prolactin identical or similar or analogous to prolactin found in a natural food source, and at least one protective layer, wherein release of said prolactin from the composition in said subject is the result of an environmental event. | 2015-06-11 |
| 20150157694 | NANO-RECOMBINANT FIBRINOGEN FOR FIBRIN SEALANTS - A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen α and chains and the γ chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO | 2015-06-11 |
| 20150157695 | MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS - A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient. | 2015-06-11 |
| 20150157696 | COMPOSITION AND METHOD FOR INHIBITING TUMOR CELL GROWTH - Polynucleotides encoding a secreted mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described. | 2015-06-11 |
| 20150157697 | LACTOFERRIN SUPPLEMENTATION AND DIARRHEA - The invention provides a composition comprising lactoferrin for use in the prevention, amelioration, or treatment of diarrhea, in particular non-infectious weaning diarrhea of infants or children. | 2015-06-11 |
| 20150157698 | Production and Application of Protozoa Cultures of Histomonas Meleagridis (H. Meleagridis) - The invention discloses a method for producing a single bacterial strain culture of | 2015-06-11 |
| 20150157699 | METHODS OF TREATING PSORIASIS USING CANDIDA ANTIGEN - A method for using a candida antigen in the treatment of psoriasis. In an embodiment, the method comprises periodically administering, to a patient having psoriasis, a candida antigen until clearance of the psoriasis is achieved. | 2015-06-11 |
| 20150157700 | ADENOVIRAL VECTOR-BASED MALARIA VACCINE - The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more | 2015-06-11 |
| 20150157701 | METHOD FOR ATTENUATING A BACTERIUM OF THE MYCOBACTERIUM TUBERCULOSIS COMPLEX FOR PRODUCING A TUBERCULOSIS VACCINE - The present invention concerns the use of a strain of a | 2015-06-11 |
| 20150157702 | PNEUMOCOCCAL SEROTYPE 6D - Disclosed is a new and emerging serotype of | 2015-06-11 |
| 20150157703 | METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS - A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal. | 2015-06-11 |
| 20150157704 | Newcastle Disease Virus Vectored Herpesvirus Vaccines - The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease. | 2015-06-11 |
| 20150157705 | THREE-DIMENSIONAL CAVITIES OF DENDRITIC CELL IMMUNORECEPTOR (DCIR), COMPOUNDS BINDING THERETO AND THERAPEUTIC APPLICATIONS RELATED TO INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) - The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells. | 2015-06-11 |
| 20150157706 | CANINE RESPIRATORY CORONAVIRUS FOR TREATMENT AND PROTECTION AGAINST BACTERIAL INFECTIONS - Provided herein are compositions, combinations, and methods comprising Canine Respiratory Coronavirus (CRCoV), which are effective in treating or preventing respiratory infections associated secondary pathogens, such as | 2015-06-11 |
| 20150157707 | COMPOSITIONS FOR TREATING AN INTESTINAL INFLAMMATORY CONDITION - Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition. | 2015-06-11 |
| 20150157708 | Conjugates for the Prevention or Treatment of Nicotine Addiction - The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): | 2015-06-11 |
| 20150157709 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist - The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease. | 2015-06-11 |
| 20150157710 | DUAL OX40 AGONIST/IL-2 CANCER THERAPY METHODS - OX40 is a potent immune stimulating target. Provided herein is a method of treating cancer, which includes administering to a subject in need of treatment an OX40 agonist and a common gamma chain (yc) cytokine or an active fragment, variant, analog, or derivative thereof. In certain aspects the common gamma chain (yc) cytokine is interleukin-2 (IL-2) or an active fragment, variant, analog, or derivative thereof. Combined treatment with an agonist anti-OX40 mAb and IL-2 synergized to augment tumor immunotherapy against multiple tumor types. Dual therapy was also able to restore the function of anergic tumor-reactive CD8+ T cells. | 2015-06-11 |
| 20150157711 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER - The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof. | 2015-06-11 |
| 20150157712 | CANCER TREATMENT - A carborane-comprising porphyrin of Formula (1) is provided for use in cancer therapy that extends the period of time between the doses required while the patient is undergoing radiation therapy. The compound can be given not more often than once every 2 or more weeks, avoiding repeated administration, while radiation therapy can continue regularly. | 2015-06-11 |
| 20150157713 | METHOD AND COMPOSITION FOR HYPERTHERMALLY TREATING CELLS - A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. | 2015-06-11 |
| 20150157714 | IMPLEMENTATION OF NON-PATHOGENIC BIOLUMINESCENT BACTERIA AS A SUB-MICRON LIGHT EMITTING SOURCE FOR PHOTO-DYNAMIC THERAPY IN THE LUNGS - Systems and methods for treating a pathogenic bacterial infection are provided. The treatment may include introducing bioluminescent bacteria into a lung of a human or animal subject, and performing photodynamic therapy on the lung using light emitted from the bioluminescent bacteria. | 2015-06-11 |
| 20150157715 | Photokinetic Ocular Drug Delivery Methods and Apparatus - The present invention relates generally to transscleral, transcorneal, and transocular delivery of biologically active substances through the tissues, blood vessels and cellular membranes of the eyes of patients without causing damage to the cellular surface, tissue or membrane. The invention provides compositions and methods for enhanced transscleral, transcorneal and transocular delivery of biologically active substances using pulsed incoherent light, and particularly the transcleral, transcorneal or transocular delivery of high molecular weight biologically active substances to a patient using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes of the eye of a subject using those compositions and methods. | 2015-06-11 |
| 20150157716 | Methods Of Identifying And Treating Poor-Prognosis Cancers - The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells. | 2015-06-11 |
| 20150157717 | Solid Dosage Form Containing a Taste Masked Active Agent - A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and release the taste masked active agent. The disintegrable film includes at least one water soluble polymer and a taste masked ketoprofen active. Also provided are methods for preparing the solid dosage form and for using the solid dosage to administer an effective dosage of an active agent, such as ketoprofen, into the oral cavity for absorption. | 2015-06-11 |
| 20150157718 | Composition to Enhance the Bioavailability of Curcumin - A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric. | 2015-06-11 |
| 20150157719 | Aqueous Gelling Compositions of Soluble Active Pharmaceutical Peptides Providing Modified Release - The present invention relates to an aqueous pharmaceutical composition comprising a peptide as the active ingredient, and one or more water-soluble or water-dispersible gelling agents. | 2015-06-11 |
| 20150157720 | ANTIMICROBIAL COMPOSITIONS CONTAINING FREE FATTY ACIDS - The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment of prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care. | 2015-06-11 |
| 20150157721 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY - The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates. | 2015-06-11 |
| 20150157722 | USE OF POLYMERIC EXCIPIENTS FOR LYOPHILIZATION OR FREEZING OF PARTICLES - Provided herein are use of polymeric excipients, specifically polyvinyl alcohols, optionally in conjunction with sugars, as cryoprotectants to prevent aggregation of PEG-containing particles. Also provided are PEG-containing particles comprising such polymeric excipients. | 2015-06-11 |
| 20150157723 | POLYCARBONATES BEARING AROMATIC N-HETEROCYCLES FOR DRUG DELIVERY - Nanoparticles comprise a drug, a first block polymer and a second block polymer. The first block polymer has a poly(ethylene oxide) (PEO) block and a polycarbonate block bearing a side chain aromatic nitrogen-containing heterocycle (N-heterocycle). The N-heterocycle can be in the form of a base, a hydrosalt of the base, a sulfobetaine adduct of the base, or a combination thereof. The second block polymer has a PEO block and a polycarbonate block bearing a side chain catechol group, which can be present as a catechol, oxidized form of a catechol, and/or a polymerized form of a catechol. The nanoparticles can be dispersed in water and are capable of controlled release of the drug. | 2015-06-11 |
| 20150157724 | Aqueous Silicone Dispersions And Their Preparation - An aqueous dispersion comprises a silicone composition dispersed in an aqueous phase. The silicone composition comprises a product of a reaction of (a) an alkenyl-containing organopolysiloxane having an average per molecule of at least 2 alkenyl groups and (b) an Si H containing siloxane having an average per molecule of at least 2 Si H moieties. The dispersion also comprises a hydrosilylation catalyst, a polymeric film former and a surfactant of molecular weight below 1600. The composition is stabilised in dispersion form by the surfactant dissolved in the aqueous phase and the polymeric film former, and is capable of forming a tacky layer on drying. | 2015-06-11 |
| 20150157725 | TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS - Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions. | 2015-06-11 |
| 20150157726 | Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions - Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection. | 2015-06-11 |
| 20150157727 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS - A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed. | 2015-06-11 |
| 20150157728 | STABILIZED AND SOLUBILIZED DRUG FORMULATION FOR TOPICAL APPLICATION AND TRANSDERMAL EFFICACY FOR COSMETIC IMPROVEMENT AND METHODS OF FORMULATION - The invention relates to a novel stabilized and solubilized topical formulation for cosmetic improvements and methods of making the same comprising multiplexed molecular penetration enhancers and essential and semi-essential amino acid protein binders for the topical application and transdermal delivery of one or more active ingredients and/or pharmaceutical agents. The invention further relates to the use of the topical formulation in connection with the providing of cosmetic improvements in individuals. | 2015-06-11 |
| 20150157729 | TOPICAL COMPOSITION COMPRISING A FILM-FORMING POLYMER FOR DELIVERING AN ACTIVE INGREDIENT TO SKIN - A sprayable film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a pharmaceutically acceptable propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethylether, and a mixture of dimethyl ether, diethylether and methylethyl ether, and a second propellant selected from C | 2015-06-11 |
| 20150157730 | Bivalent Ligands for the Treatment of Neurological Disorders - Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS. | 2015-06-11 |
| 20150157731 | TRANSGENIC PLANTS EXPRESSING COBALAMIN BINDING PROTEINS - The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins. | 2015-06-11 |
| 20150157732 | ZWITTERIONIC POLYMER BIOCONJUGATES AND RELATED METHODS - Zwitterionic polymer and mixed charge copolymer bioconjugates, methods for making and using the bioconjugates. | 2015-06-11 |
| 20150157733 | POLYETHYLENE GLYCOL DERIVATIVES OF PALMITOYLETHANOLAMIDE AND ANALOGOUS ACYLETHANOLAMIDES - The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues—particularly in the skin and mucosae—and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects. | 2015-06-11 |
| 20150157734 | OLIGOMER-BIS-CHROMONYL COMPOUND CONJUGATES - The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds. | 2015-06-11 |
| 20150157735 | PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY - The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as | 2015-06-11 |
| 20150157736 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE - The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. | 2015-06-11 |
| 20150157737 | Polymers for Functional Particles - A method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. The nanoparticle may contain a drug. The moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other methods use such libraries, use or administer such polymeric conjugates, or promote the use of such polymeric conjugates. Kits involving such polymeric conjugates are also described. | 2015-06-11 |
| 20150157738 | Papillomavirus Pseudoviruses for Detection and Therapy of Tumors - Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP) | 2015-06-11 |
| 20150157739 | Imidazo[2,1]thiazol-3-one derivatives - The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula | 2015-06-11 |
| 20150157740 | METHOD FOR MANUFACTURING BIOMEDICAL SIGNAL CONDUCTIVE MEMBRANE - A method for manufacturing a biomedical signal conductive membrane includes providing a natural polymer material, adding an acid solution for making the natural polymer material dissolved in the acid solution to form a viscous liquid mixture, performing a dry step for drying the viscous liquid mixture to form an initial stage of membrane, wherein the structure of natural polymer material within the initial stage of membrane is a straight chain, providing a cross-linking agent to perform a cross-linking step for transforming the initial stage of membrane into a gel membrane, wherein the structure of natural polymer material within the gel membrane is a cross-linked network, and performing a rinse step for removing the cross-linking agent and keeping a plurality of water molecules remaining within the cross-linked network of natural polymer material. | 2015-06-11 |
| 20150157741 | COMPOUND AND PHOTOACOUSTIC IMAGING CONTRAST MEDIUM CONTAINING THE COMPOUND - The present invention provides a compound which exhibits a high degree of accumulation into a tumor even when some extent of time has passed after performing administration and which facilitates an increase in the intensity of photoacoustic signal produced by the tumor. | 2015-06-11 |
| 20150157742 | SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225 - A method is described for producing a radioconjugate labeled with radionuclide Ac-225 comprising the step of chelating said radionuclide Ac-225 with a conjugated chelate compound in a chelation reaction mixture to obtain a radioconjugate labeled with Ac-225, wherein the pH of the chelation reaction mixture is comprised between 7.1 and 10, preferably between 8.0 and 9.5, more preferably about 9.0. | 2015-06-11 |
| 20150157743 | Dose Synthesis Card for Use with Automated Biomarker Production System - Microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, ten (10) unit doses of radiopharmaceutical biomarker for use in positron emission tomography (PET). A radioisotope from an accelerator or other radioisotope generator is introduced into a reaction vessel, along with organic and aqueous reagents, and the mixture heated to synthesize a solution of a pre-selected radiopharmaceutical. The solution is purified by passing through a combination of solid phase extraction purification components, trap and release components, and a filter. The synthesis process reduces waste and allows for production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between synthesis of the radiopharmaceutical and administration of that radiopharmaceutical, minimizing loss of active isotopes through decay and allowing production of lesser amounts of radioisotopes overall. | 2015-06-11 |
| 20150157744 | TREATMENT OF MENINGIOMAS USING PHENYLBENZOTHIAZOLE, STILBENE, BIPHENYLALKYNE, OR PYRIDINE DERIVATIVES - A method and composition for treating a meningioma in a subject are disclosed. The method includes the step of administering to the subject a therapeutically effective amount of a composition including a cytotoxic agent associated with a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative that accumulates within meningiomas. In one version of the method, the phenylbenzothiazole derivative is a compound of formula (V). | 2015-06-11 |
| 20150157745 | PROBE FOR A BIOLOGICAL SPECIMEN AND LABELLING METHOD AND SCREENING METHOD USING THE PROBE - Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent spectral characteristics and exhibiting excellent storage stability. The probe for a biological specimen contains, as an active agent, at least one kind of compound represented by a general formula (I). | 2015-06-11 |
| 20150157746 | MACROCYCLES - The invention provides macrocycles useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications. | 2015-06-11 |
| 20150157747 | COMPOUNDS WITH REDUCED RING SIZE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME - The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 2015-06-11 |
| 20150157748 | Antibodies that Bind Activatable Antibodies and Methods of Use Thereof - The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies. | 2015-06-11 |
| 20150157749 | Reusable Grocery Bag Disinfection Machine - The introduction of reusable grocery bags has lead to contamination of these bags by bacteria, virus and | 2015-06-11 |
| 20150157750 | METHOD FOR STERILIZING MEMBRANE COMPRISING GLUCOSE OXIDASE AND ASSOCIATED BIO-SENSOR - A method for sterilizing a membrane comprising an oxidoreductase enzyme, comprises: irradiating with gamma radiation the membrane comprising an oxidoreductase enzyme soaked in an aqueous buffer solution. Associated biosensors and bioreactors are also described. | 2015-06-11 |
